Skip to main content
. 2022 Aug 10;23(1):98. doi: 10.1186/s10194-022-01469-x

Fig. 4.

Fig. 4

Effect of the DRD2 antagonist sulpiride on pain behaviors and GLUA1 trafficking. A, B and C The mechanical, thermal, and periorbital pain thresholds after sulpiride (30 µg) injection. Two-way ANOVA with the Bonferroni post hoc test; n = 6/group; ***P < 0.05 vs. the Sham group; #P < 0.05, ###P < 0.001 vs. the CM + DMSO group. D-G, Immunoblot analysis indicated that the protein levels of p-ERK and PSD95 and the plasma membrane level of GLUA1 were further elevated by sulpiride. One-way ANOVA with Dunnett’s post hoc test; n = 6/group; *P < 0.05, **P < 0.01, ***P < 0.001 vs. the Sham + DMSO group; #P < 0.05, ##P < 0.01, ###P < 0.001 vs. the CM + DMSO group